更新于：2024-11-04
Voriconazole
伏立康唑
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol、(αR,βS)-α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol、Inhaled Voriconazole + [18] |
靶点 |
作用机制 CYP51A1抑制剂(细胞色素P450家族成员51抑制剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C16H14F3N5O |
InChIKeyBCEHBSKCWLPMDN-MGPLVRAMSA-N |
CAS号137234-62-9 |
关联
257
项与 伏立康唑 相关的临床试验A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants
注射用伏立康唑在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹生物等效性试验
研究方案
Study on the mechanism of toxicity induced by voriconazole in central nervous system based on metabolomics
100 项与 伏立康唑 相关的临床结果
登录后查看更多信息
100 项与 伏立康唑 相关的转化医学
登录后查看更多信息
100 项与 伏立康唑 相关的专利（医药）
登录后查看更多信息
8,260
项与 伏立康唑 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity
Review
作者: Xing, Shubin ; Zhao, Xiaodong ; Tang, Xuemei ; Zhang, Zhenzhen ; An, Yunfei ; Liu, Cong ; He, Wuyang ; Chen, Yongwen ; Zhang, Wenjing ; Zhang, Zhiyong
BACKGROUND:
Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.
OBJECTIVE:
We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.
METHODS:
A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.
RESULTS:
Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.
CONCLUSIONS:
The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Disseminated Aspergillosis in X-linked Agammaglobulinemia: Beyond the norm
Article
作者: Rawat, Amit ; Vignesh, Pandiarajan ; Jindal, Ankur Kumar ; Thangaraj, Abarna ; Goel, Sumit ; Sil, Archan
X-linked agammaglobulinemia (XLA) due to a mutation in Bruton's tyrosine kinase (BTK), leads to the arrested development of B cells at the pro-B cell stage. This results in absent B cells and severe hypogammaglobulinemia. XLA patients usually present with recurrent sinopulmonary infection. Bacterial infections are the commonest [2], fungal infections like Pneumocystis jirovecii, Aspergillus and Candida species are rarely reported and they are associated with mortality in XLA [3]. We report a 3.5-year-old boy with disseminated aspergillosis, an uncommon presentation of XLA. Despite treatment with antifungals, including voriconazole and amphotericin B, the patient succumbed to the illness. Genetic analysis revealed a pathogenic variant in the BTK gene (R28H), confirming XLA diagnosis. This case highlights the potential for severe fungal infections in XLA patients and suggests broader immune system dysregulation beyond B-cell defects.
2025-02-01PARASITOLOGY INTERNATIONAL
Pulmonary infection by Lophomonas spp. and Aspergillus spp. in a B-cell acute lymphocytic leukemia patient from Chile
Article
作者: Cabrera, Johanna ; Moenen-Locoz, Enzo ; Chahin, Carolina ; Briones, Javier ; Hidalgo, Alejandro ; Iturrieta-González, Isabel ; Fonseca-Salamanca, Flery ; Vega, Fernando ; Concha, Carla
The flagellated protozoan Lophomonas spp. is a commensal microorganism found in the intestinal tracts of cockroaches, termites, mites, and certain birds. It is the causative agent of a rare infection in humans called lophomoniasis, primarily affecting the lungs and mainly immunocompromised individuals. This parasitosis is transmitted to humans by air or through ingestion of the cystic forms of the parasite. We describe the case of a 50-year-old patient treated at a tertiary hospital in southern Chile with a history of B-cell acute lymphocytic leukemia. Radiological findings, along with increased levels of inflammatory parameters and galactomannan antigen in serum and Bronchoaveolar Lavage (BAL) raised the suspicion of a pulmonary infection. Microscopic study of BAL revealed oval to pyriform cells with mobile flagella at the anterior end, which were identified as Lophomonas spp. trophozoites, which based on EORTC/MSG criteria were associated with diagnosis of a probable pulmonary aspergillosis. Lophomoniasis was treated with metronidazole (500 mg IV every 8 h) for 14 days and pulmonary aspergillosis required a combination of fluconazole, voriconazole, anidulafungin, liposomal amphotericin B and isavuconazole. The patient responded favorably and was discharged after 95 days of hospitalization. This case highlights the importance of recognizing lophomoniasis as a parasitic infection in respiratory samples from immunocompromised patients who present pulmonary symptoms, especially those who do not respond satisfactorily to conventional antimicrobial treatments. Further research is needed to understand the various sources of Lophomonas spp. infection and develop infection prevention strategies particularly for high-risk patients.
100 项与 伏立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 系统性念珠菌病 | 美国 | 2017-03-09 | |
| 侵袭性念珠菌病 | 欧盟 | 2013-05-16 | |
| 侵袭性念珠菌病 | 冰岛 | 2013-05-16 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2013-05-16 | |
| 侵袭性念珠菌病 | 挪威 | 2013-05-16 | |
| 茎孢子虫病 | 美国 | 2003-12-19 | |
| 镰刀菌病 | 美国 | 2002-05-24 | |
| 念珠菌血症 | 欧盟 | 2002-03-19 | |
| 念珠菌血症 | 冰岛 | 2002-03-19 | |
| 念珠菌血症 | 列支敦士登 | 2002-03-19 | |
| 念珠菌血症 | 挪威 | 2002-03-19 | |
| 念珠菌病 | 欧盟 | 2002-03-19 | |
| 念珠菌病 | 冰岛 | 2002-03-19 | |
| 念珠菌病 | 列支敦士登 | 2002-03-19 | |
| 念珠菌病 | 挪威 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 欧盟 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 冰岛 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 列支敦士登 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 挪威 | 2002-03-19 | |
| 侵袭性真菌感染 | 欧盟 | 2002-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白血病 | 临床3期 | 美国 | 2009-05-01 | |
| 肺曲霉菌病 | 临床3期 | 法国 | 2005-07-01 | |
| 发热 | 临床3期 | 德国 | 2005-01-01 | |
| 腔内曲霉菌球 | 临床2期 | 日本 | 2011-09-01 | |
| 全身性真菌病 | 临床2期 | 美国 | 2008-06-01 | |
| 中性粒细胞减少 | 临床2期 | - | 2003-06-01 | |
| 侵袭性肺曲霉菌病 | 临床2期 | - | - | |
| 真菌性角膜炎 | 临床1期 | 中国 | 2023-07-17 | |
| 哮喘 | 临床1期 | 澳大利亚 | 2020-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | 鏇願衊鹹憲夢願鏇簾構(淵廠繭衊鑰範糧積醖選) = 製鹽壓襯衊範夢夢獵鹽 餘糧鏇襯顧艱淵鹹觸鏇 (築糧鏇襯淵糧獵簾繭夢 ) 更多 | 不佳 | 2024-05-14 | |||
GlobeNewswire 人工标引  | 临床2期 | 9 | TFF VORI | 選夢鏇鹹鑰憲網鹹簾製(齋範窪製夢獵夢積糧齋) = 顧齋觸鬱餘壓製網膚艱 顧簾醖壓鬱鹽襯襯範憲 (夢壓衊積淵製醖選蓋鑰 ) 更多 | 积极 | 2023-12-19 | |
- | |||||||
N/A | - | 17 | Microdosed midazolam | 遞淵製鑰網鏇積鹽鏇簾(衊憲範範構顧夢願鬱構) = 衊簾齋襯選淵艱顧構醖 鏇構鬱製壓築鑰糧糧簾 (夢簾鏇顧夢網鏇願醖築 ) | - | 2023-07-28 | |
临床1期 | - | 48 | 顧淵糧淵網獵鬱鑰顧膚(壓遞窪製願膚繭築遞顧) = 廠築膚鹽構憲繭蓋願襯 鹽鑰顧壓遞壓鹹顧網築 (窪鏇構廠淵鏇糧鬱鑰襯 ) 更多 | - | 2023-03-03 | ||
顧淵糧淵網獵鬱鑰顧膚(壓遞窪製願膚繭築遞顧) = 艱膚鑰鑰願廠遞衊觸餘 鹽鑰顧壓遞壓鹹顧網築 (窪鏇構廠淵鏇糧鬱鑰襯 ) 更多 | |||||||
临床3期 | 85 | 鹹鑰齋選糧鬱膚齋壓獵(襯鏇餘齋蓋醖鏇襯積糧) = 鹽鏇餘積獵網網繭憲壓 選廠襯壓簾顧鹹夢鬱製 (齋夢鬱廠齋糧鏇壓衊蓋 ) 更多 | 积极 | 2023-03-01 | |||
鹹鑰齋選糧鬱膚齋壓獵(襯鏇餘齋蓋醖鏇襯積糧) = 夢衊願夢壓鹹淵願範鏇 選廠襯壓簾顧鹹夢鬱製 (齋夢鬱廠齋糧鏇壓衊蓋 ) 更多 | |||||||
临床3期 | 189 | (TDM group) | 願遞遞鏇醖廠觸餘淵膚(齋艱鬱觸願襯齋餘糧網) = 顧壓膚鏇鹽選積夢製醖 齋鏇鹹壓獵簾艱鹹糧鏇 (襯網襯齋網壓壓網積齋 ) | - | 2023-01-12 | ||
(non-TDM group) | 願遞遞鏇醖廠觸餘淵膚(齋艱鬱觸願襯齋餘糧網) = 製糧襯餘範範齋鹽鏇淵 齋鏇鹹壓獵簾艱鹹糧鏇 (襯網襯齋網壓壓網積齋 ) | ||||||
临床3期 | 82 | 製鑰築積積憲範艱窪蓋(積膚衊憲築繭簾構蓋鑰) = 鹹膚觸遞醖構範餘觸醖 鹹網膚齋糧憲選築醖遞 (觸製糧窪製餘夢遞網壓 ) 更多 | 积极 | 2022-11-04 | |||
製鑰築積積憲範艱窪蓋(積膚衊憲築繭簾構蓋鑰) = 範繭範願艱選網鏇網鹽 鹹網膚齋糧憲選築醖遞 (觸製糧窪製餘夢遞網壓 ) 更多 | |||||||
N/A | - | 468 | Voriconazole (VCZ) | 築衊襯艱範餘餘築繭憲(醖艱觸餘積糧襯衊鏇壓) = 廠鹹鹹鹽糧鬱壓鹽願簾 簾糧壓壓繭積憲鏇願糧 (鹽鏇獵簾夢艱選繭鹹夢 ) 更多 | 积极 | 2022-03-01 | |
N/A | - | 選齋夢鑰範齋淵蓋醖廠(獵齋構齋積獵襯淵衊鑰): aOR = 0.543 (95% CI, 0.338 ~ 0.872) 更多 | - | 2022-01-01 | |||
N/A | 造血干细胞移植 CYP2C19*17 | 70 | Letermovir prophylaxis | 鏇憲衊構窪鬱鏇膚膚齋(顧簾蓋製鬱鏇築膚獵積) = 積衊觸鏇築壓鹹鹹蓋餘 齋窪獵夢範獵廠襯遞淵 (鑰顧廠鑰範壓鹹鏇衊齋 ) | - | 2021-03-01 | |
No Letermovir prophylaxis | 鏇憲衊構窪鬱鏇膚膚齋(顧簾蓋製鬱鏇築膚獵積) = 齋選顧築夢齋膚遞憲齋 齋窪獵夢範獵廠襯遞淵 (鑰顧廠鑰範壓鹹鏇衊齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用